Blue 2

Blue 2, also known as Indigotine or Indigo Carmine, is a synthetic food dye in the indigoid chemical family. It imparts a distinctive indigo-blue color to food and beverages and is one of the certified color additives permitted for use in the United States, the European Union, and many other jurisdictions worldwide.

The dye is produced by sulfonation of indigo, itself derived from synthetic chemical precursors. While its historical roots trace back to the natural indigo plant dye, the commercial form used in food is entirely synthetic. Blue 2 is water-soluble and relatively stable under normal food-processing conditions, though it is sensitive to light and reducing agents.

Regulatory bodies including the U.S. Food and Drug Administration (FDA) and the European Food Safety Authority (EFSA) have evaluated Blue 2 and established acceptable daily intakes (ADIs), concluding it is safe at levels typically encountered in food. However, the dye has faced scrutiny over a 2007 UK study linking certain color mixes to hyperactivity in children, and it carries an advisory label requirement in the EU as a result of that broader regulatory response.

Scientific evidence on potential adverse effects remains limited and sometimes contested. Public debate continues, particularly regarding children's sensitivity to synthetic dyes, though major regulatory agencies have not found sufficient cause to withdraw approval.

Blue 2 (Indigo Carmine) belongs to the indigoid class of dyes, characterised by a bicyclic indigo core. Its IUPAC name is disodium (2E)-2-[(3E)-3-(2-oxo-1H-indol-3-ylidene)-2-oxo-2,3-dihydro-1H-indol-5-ylsulfonato]indole-5-sulfonate. The molecule consists of two oxindole rings joined by a central carbon–carbon double bond, giving rise to the extended conjugated system responsible for light absorption in the red–orange region (~610 nm), which produces the perceived blue-indigo color. Two sulfonate groups (–SO₃Na) attached to the indole rings confer water solubility and account for the anionic character of the dye at food-relevant pH values. The sodium salt form (disodium indigotine) is the commercially used species. The dye lacks free amino groups and is not considered an azo dye, distinguishing it chemically from dyes such as Red 40 or Yellow 5.

Commercial Blue 2 is produced by the chemical sulfonation of synthetic indigo. The process begins with the synthesis of indigo itself, typically via the Heumann–Pfleger process or related routes, starting from aniline or anthranilic acid derivatives combined with chloroacetic acid (or other reagents) to yield indoxyl intermediates that are air-oxidised to indigo. The purified indigo is then treated with fuming sulfuric acid (oleum) at controlled temperatures, introducing two sulfonate groups at the 5 and 5′ positions of the indigo molecule. The resulting crude indigotine is neutralised with sodium hydroxide or sodium carbonate to form the disodium salt, then purified by filtration, washing, and drying. The final product is milled to a fine powder, standardized for dye content (typically ≥85% pure dye as specified by regulatory standards), and batch-certified by the FDA or equivalent authority before commercial release for food use.

The history of Blue 2 is intertwined with that of natural indigo, one of humanity's oldest dyes, extracted from plants of the genus Indigofera and used for thousands of years in textile dyeing across Asia, Africa, and the Americas. The synthetic route to indigo was pioneered by Adolf von Baeyer in 1878, and full industrial synthesis was commercialised by BASF in 1897, effectively displacing the natural crop. Sulfonation of indigo to produce the water-soluble indigo carmine form for textile use dates to the mid-19th century. With the growth of the synthetic dye industry, indigo carmine entered food use in the early 20th century. In the United States, it was included among the original batch of certified dyes permitted under the Federal Food, Drug, and Cosmetic Act of 1938 and was subsequently listed as FD&C Blue No. 2. In the European Union, it received the E132 designation under successive food additive directives. Periodic re-evaluations by FDA and EFSA have maintained its permitted status, though the 2007 McCann study on synthetic dyes and children's behavior prompted the EU to require advisory labeling on products containing it.

• Color standardisation: Provides a consistent, reproducible indigo-blue hue in finished products regardless of batch or season.
• Consumer appeal: Blue and violet shades are uncommon in natural foods; Blue 2 creates visually distinctive products (e.g., blue confectionery, sports drinks).
• Blending versatility: Combined with yellow or red dyes to produce a wide palette of greens, purples, and blacks in complex food formulations.
• Stability in processing: Withstands pasteurisation and moderate heat processing better than many natural blue pigments such as anthocyanins.
• Cost-effectiveness: Synthetic production yields a highly purified, consistent, and relatively inexpensive colourant compared to equivalent natural alternatives.
• Low use-level efficacy: Intense color at low concentrations minimises cost and potential flavor impact.

None established. Blue 2 is a colourant added purely for aesthetic purposes. It provides no nutritional value, no functional physiological benefit, and no established protective effect against any disease or condition. It is not a source of macronutrients, micronutrients, antioxidants, or bioactive compounds at food-use concentrations.

Hypersensitivity and Allergy (Limited Evidence)

A small number of case reports and clinical observations have documented hypersensitivity reactions—including urticaria (hives) and, rarely, anaphylactoid responses—to ingested indigo carmine. The evidence base is restricted to case series and is not derived from controlled trials, so prevalence estimates are uncertain. Individuals with known dye sensitivities are generally advised to avoid products containing Blue 2.

Hyperactivity in Children (Emerging / Contested Evidence)

The 2007 McCann et al. study published in The Lancet reported a statistically significant association between a mixture of synthetic food colors (including Blue 2 in some test mixtures) and increased hyperactivity in 3-year-old and 8–9-year-old children. Importantly, the study used a mixture of six dyes plus sodium benzoate, making it impossible to attribute the effect to any single dye. EFSA's 2008 review concluded the findings could not be used to establish an ADI revision but acknowledged the signal warranted the EU advisory label. The FDA's 2011 review by its Food Advisory Committee found insufficient evidence of a causal link to require labeling changes in the US. This remains an area of ongoing but unresolved scientific debate.

Intravenous Use Risks (Established — Not Relevant to Food)

Indigo carmine is used medically as an intravenous diagnostic agent. In that clinical context, cardiovascular effects (hypertension, bradycardia) and severe anaphylaxis have been well documented. These risks are not relevant to dietary exposure at food-additive levels, which are far lower than medical doses and delivered via a different route.

Animal Carcinogenicity Studies (Limited / Inconclusive)

Older rodent feeding studies produced equivocal findings at very high doses. Regulatory bodies have not classified Blue 2 as carcinogenic to humans based on available evidence, and the doses associated with tumour formation in some animal studies greatly exceed plausible human dietary exposure. See the Animal Studies section for further detail.

The Joint FAO/WHO Expert Committee on Food Additives (JECFA) has established an Acceptable Daily Intake (ADI) of 5 mg/kg body weight per day for indigo carmine. The European Food Safety Authority (EFSA) reaffirmed this ADI in its 2010 re-evaluation. The U.S. FDA has not formally published a numerical ADI but has established use levels through its certification and listing process; estimated daily intakes from food for the U.S. population are well below the JECFA ADI.

Children: Due to lower body weight, children's per-kilogram intake from equivalent servings is proportionally higher than adults'. Dietary exposure modeling by EFSA and FDA suggests intake remains within the ADI under normal consumption patterns, though high consumers of highly coloured confectionery and soft drinks may approach the ADI. The EU advisory label ('may have an adverse effect on activity and attention in children') is intended to inform parents.

Pregnancy and lactation: No specific ADI modification exists for pregnant or lactating individuals. No teratogenicity has been established in standard animal studies at food-relevant doses. Precautionary avoidance is sometimes recommended by healthcare providers due to general uncertainty, though no regulatory body mandates this.

Allergic individuals: Those with documented hypersensitivity to Blue 2 or other synthetic dyes should avoid products containing it, regardless of dose.

The bulk of peer-reviewed research on Blue 2 / Indigo Carmine in the food-safety context clusters around three areas: genotoxicity/carcinogenicity, behavioural effects, and metabolic fate.

Metabolism and absorption: Studies in rodents and humans indicate that Blue 2 is poorly absorbed in the gastrointestinal tract. The majority is excreted unchanged in faeces; a small fraction undergoes bacterial reduction in the colon, producing isatin-5-sulfonic acid and aniline-2-sulfonic acid as principal metabolites. These metabolites are absorbed and excreted in urine. A key study by Renwick (1986) and subsequent JECFA reviews confirmed limited systemic bioavailability, which is relevant to risk assessments.

Genotoxicity: In vitro Ames test results for Blue 2 have generally been negative or equivocal at food-relevant concentrations. Some older studies reported weak mutagenic signals at very high concentrations in certain bacterial strains, but these have not been replicated consistently and are not considered biologically significant at dietary exposure levels by JECFA or EFSA.

Carcinogenicity: A 1979 National Cancer Institute (NCI) bioassay reported an increase in brain tumours (specifically gliomas) in male rats fed diets containing very high doses of Blue 2. This finding led to re-evaluation by the FDA, which ultimately concluded—based on dose-response modeling and the extreme doses required—that the risk to humans at ADI-consistent intake levels was not established. Subsequent studies and JECFA evaluations did not alter the approved status, though the brain tumour finding remains a noted data point in regulatory history.

Behavioural effects: The 2007 McCann et al. double-blind, randomised, placebo-controlled trial (The Lancet, doi:10.1016/S0140-6736(07)61306-3) found increased hyperactivity scores in children consuming a mixture of synthetic dyes including those in the EU-approved palette (Blue 2 was present in some formulations). Methodological limitations—chiefly the use of mixtures rather than individual dyes—prevent definitive attribution. EFSA (2008) and the FDA Food Advisory Committee (2011) both reviewed this evidence and did not find it sufficient to revise ADIs or mandate labeling changes beyond those already in place in the EU.

Blue 2 has been drawn into the broader public controversy over synthetic food dyes that intensified following the 2007 McCann et al. 'Southampton study.' Advocacy groups—particularly the Center for Science in the Public Interest (CSPI) in the United States—have repeatedly petitioned the FDA to ban Blue 2 along with other certified dyes, citing the hyperactivity research and historical carcinogenicity concerns. Media coverage has frequently characterised the dye as definitively harmful to children, often overstating the strength of the hyperactivity evidence and conflating the mixture study results with effects specific to Blue 2.

The EU's 2010 decision to require the advisory label 'may have an adverse effect on activity and attention in children' on products containing the Southampton six dyes (which includes Blue 2 in some EU formulations) was widely interpreted in popular media as a partial ban, when it is in fact a disclosure requirement. This nuance has been lost in much public communication. The label requirement prompted many UK and European manufacturers to voluntarily reformulate products with natural alternatives such as spirulina extract or butterfly pea flower, reducing but not eliminating Blue 2 use in Europe.

A separate strand of concern relates to the historical NCI rat carcinogenicity finding, which resurfaces periodically in online health articles without the contextualising detail about dose levels or regulatory re-evaluation. No major food regulatory authority currently classifies Blue 2 as a known or probable human carcinogen.

Indigo carmine, like other synthetic azo and non-azo textile and food dyes, has received attention in the context of industrial wastewater treatment, though the food-grade dye is produced and used in far smaller quantities than its textile counterpart. The dye is water-soluble and chromophoric at low concentrations, meaning even small quantities can cause visible discolouration of receiving water bodies if inadequately treated. Laboratory studies have demonstrated that indigo carmine can be degraded by advanced oxidation processes (AOPs), ozone treatment, and certain microbial consortia under anaerobic conditions; however, reductive degradation can produce aromatic amine intermediates that may carry their own environmental hazard, a concern more acute in textile effluents than in food-production wastewater.

The ecological toxicity of Blue 2 at environmental concentrations arising from food manufacturing has not been extensively characterised in field studies. Regulatory environmental assessments have generally focused on direct human health risk rather than ecosystem impacts. As volumes used in food are relatively small compared to industrial textile applications, the environmental footprint from food-grade Blue 2 specifically is considered modest, though it is not negligible when aggregated across global production.

Workers involved in the manufacture, milling, and handling of Blue 2 powder face potential occupational exposure via inhalation of fine dye particles and dermal contact. As an anionic dye, skin staining is a common and largely cosmetic concern. More substantive occupational health concerns relate to respiratory sensitisation: fine dye dust, like many fine organic particulate materials, can act as a respiratory irritant or sensitiser with repeated exposure. There are limited published occupational epidemiology data specific to indigo carmine workers, as opposed to the broader dye-manufacturing workforce.

Standard industrial hygiene practices—including enclosed handling systems, local exhaust ventilation, respiratory protective equipment (RPE), and skin/eye protection—are recommended for workers handling dry Blue 2 powder. Regulatory occupational exposure limits (OELs) specific to indigotine are not universally established; general nuisance-dust limits are typically applied in the absence of a substance-specific OEL.

The most consequential animal study for Blue 2's regulatory history is the 1979 National Cancer Institute (NCI) bioassay in which male and female Fischer 344 rats were fed diets containing 2% Blue 2 (approximately 1,000–2,000 mg/kg body weight/day) for up to 110 weeks. A statistically significant increase in brain gliomas was observed in male rats. This finding triggered an immediate FDA re-review and was subsequently evaluated by JECFA. The extremely high doses—orders of magnitude above the established ADI—and the absence of replication in subsequent well-controlled studies led regulatory bodies to conclude the data did not establish an acceptable risk at dietary exposure levels, though the finding was not dismissed outright and remains documented in the regulatory record.

Subsequent subchronic and chronic feeding studies in rodents at lower, more physiologically relevant doses did not reproduce the glioma finding. Reproductive and developmental toxicity studies in standard models have not identified teratogenic or reproductive effects at doses near or below the ADI. In vitro and in vivo genotoxicity assays (Ames test, micronucleus assay) have largely produced negative results, supporting the interpretation that Blue 2 is not a direct-acting genotoxic carcinogen.

Controlled human studies specifically isolating Blue 2's effects are sparse. The most cited human evidence remains the 2007 McCann et al. randomised double-blind crossover trial in two cohorts of UK children (3-year-olds and 8–9-year-olds), which used two commercial dye mixes—'Mix A' (including Blue 2 equivalent) and 'Mix B'—combined with sodium benzoate. Statistically significant increases in a composite hyperactivity measure were reported for both mixes relative to placebo in both age groups. However, because the intervention was a multi-component mixture and not a single-dye challenge, causal attribution to Blue 2 specifically cannot be derived from this study. A 2012 meta-analysis by Nigg et al. (J Atten Disord) examined the cumulative literature and concluded that the overall effect size of food dye removal on hyperactivity was modest but statistically detectable, again without isolating individual dyes.

Pharmacokinetic data from human volunteer studies confirm that orally ingested indigotine is largely unabsorbed, with the majority passing through the gastrointestinal tract intact. Urinary excretion of the isatin-5-sulfonic acid metabolite occurs at low levels reflecting partial colonic reduction. No controlled human studies have evaluated dose–response relationships for adverse effects at doses below or near the ADI, which represents a gap in the evidence base identified in successive regulatory re-evaluations.

In the United States, Blue 2 must be declared on food labels by its full name FD&C Blue No. 2 or the abbreviated form Blue 2. Certification statements ('Certified Color: FD&C Blue No. 2') may also appear on ingredient labels of batch-certified products.

In the European Union, products containing Blue 2 (E132) must list 'E132' or 'Indigo Carmine' in the ingredients list. Additionally, any food or beverage containing Blue 2 as one of the six 'Southampton colors' must carry the mandatory advisory statement: 'may have an adverse effect on activity and attention in children', per EU Regulation (EC) No 1333/2008 as amended.

In Australia and New Zealand, Blue 2 appears on labels as 'Color (132)' or 'Color (Indigo Carmine)' under the FSANZ labeling standard.

In Canada, it appears as 'Indigo (FD&C Blue No. 2)' in the ingredient list.

Common alternative names that may appear on labels include: Indigotine, Indigo Carmine, Acid Blue 74, CI Food Blue 1, E132.

Indigo carmine as used in food is entirely synthetic and does not occur naturally in any food ingredient. However, its chemical precursor, indigo, is found in small quantities in the leaves of various plants of the genus Indigofera (indigo plants) as well as in woad (Isatis tinctoria) and certain other plant species, where it exists as its glucoside precursor indican. These plant-derived sources of indigo are used in natural textile dyeing and are not the source of commercial food-grade Blue 2, which is produced entirely by chemical synthesis. No common food naturally contains measurable quantities of indigotine or a bioequivalent blue indigoid pigment at levels relevant to color contribution.